Research ArticleOpen AccessGoogle Scholar indexed
The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
- 1 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
- 2 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
- 3 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
- 4 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
- 5 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
- 6 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
- 7 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
- 8 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
Journal of Crystallization Process and Technology·Volume 04 (2014)·Pages 27–30·Published 2 January 2014·DOI10.4236/jcpt.2014.41004
Copy link · social · email
Abstract
Objective: To determine the transformation between two known crystal forms of the title compound (C 18 H 23 NO 3 , Mr = 301.37). Methods: To recrystallize or heat the crystals and determine the crystal form by testing the melting points. Results: Both the two known crystal forms of the title compound can be changed by dissolving into different organic solvents such as acetone and ethyl acetate. Crystal form I was not influenced by heating while crystal form II can be transformed to crystal form I through melting method. Conclusion: Organic solvents have significant influences on the two crystal forms of title compound. Crystal form I shows a better thermal stability than crystal form II .
KeywordsSU2162PolymorphismCrystal FormMelting MethodSolvent Method
- FDA, “FDA PAT Page.” http://www.fda.gov/cder/OPS/PAT.htm
- L. X. Yu, R. A. Lionberger, A. S. Raw, et al., “Applications of Process Analytical Technology to Crystallization Processes,” Advanced Drug Delivery Reviews, Vol. 56, No. 3, 2004, pp. 349-369. http://dx.doi.org/10.1016/j.addr.2003.10.012
- A. V. Trask, “An Overview of Pharmaceutical Cocrystals as Intellectual Property,” Molecular Pharmacology, Vol. 4, No. 3, 2007, pp. 301-309. http://dx.doi.org/10.1021/mp070001z
- R. Siegel, D. Naishadham, A. Jemal, et al., “Cancer Statistics, 2013,” CA: A Cancer Journal for Clinicians, Vol. 63, No. 6, 2013, pp. 11-30. http://dx.doi.org/10.3322/caac.21166
- Z.-Y. Tan, K. Liang, H. Zhang, et al., “Preparation of a Derivative of Cantharidin with Anticancer Activity,” China Patent No. 200710029736, 2008/
- Z.-Y. Tan, L. Luo, E.-J. Zhu, et al., “Preparation and X-Ray Diffraction Analysis of a New Crystal Form of (3aRS, 4SR, 7RS, 7aSR)-2-(Tricyclo [3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione—A Novel Anticancer Compound,” Journal of Guangdong Pharmaceutical College, Vol. 26, No. 6, 2010, pp. 572- 575.
- Z.-Y. Tan, E.-J. Zhu, L. Luo, et al., “A Method of Inhibiting Platelet Aggregation, Anti-Thrombosis Ferulic Acid Crystal and Preparation Method,” TMP: China Patent No. ZL201010562477.0, 2013.
- Z.-Y. Tan, L. Luo, E.-J. Zhu, et al., “(3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione,” Acta Crystallographica, Vol. E66, 2010, Article ID: o1374.